Advagene Biopharma Co (ROCO:6709) Total Assets : NT$93.90 Mil (As of Jun. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Advagene Biopharma Co Total Assets?

Advagene Biopharma Co's Total Assets for the quarter that ended in Jun. 2023 was NT$93.90 Mil.

During the past 12 months, Advagene Biopharma Co's average Total Assets Growth Rate was -39.90% per year. During the past 3 years, the average Total Assets Growth Rate was -19.00% per year. During the past 5 years, the average Total Assets Growth Rate was -6.40% per year.

During the past 8 years, Advagene Biopharma Co's highest 3-Year average Total Assets Growth Rate was 17.10%. The lowest was -19.00%. And the median was -2.40%.

Total Assets is connected with ROA %. Advagene Biopharma Co's annualized ROA % for the quarter that ended in Jun. 2023 was -79.46%. Total Assets is also linked to Revenue through Asset Turnover. Advagene Biopharma Co's Asset Turnover for the quarter that ended in Jun. 2023 was 0.00.

Advagene Biopharma Co Total Assets Historical Data

The historical data trend for Advagene Biopharma Co's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Advagene Biopharma Co Total Assets Chart

Advagene Biopharma Co Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Assets

Get a 7-Day Free Trial

279.22

316.26

260.41

140.84

147.93

Advagene Biopharma Co Semi-Annual Data
	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Total Assets	Get a 7-Day Free Trial										260.41	201.80	140.84	93.90	147.93

Advagene Biopharma Co Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Advagene Biopharma Co's Total Assets for the fiscal year that ended in Dec. 2023 is calculated as

Total Assets	=	Total Equity (A: Dec. 2023 )	+	Total Liabilities (A: Dec. 2023 )
	=	139.962	+	7.972
	=	147.93

Advagene Biopharma Co's Total Assets for the quarter that ended in Jun. 2023 is calculated as

Total Assets	=	Total Equity (Q: Jun. 2023 )	+	Total Liabilities (Q: Jun. 2023 )
	=	85.133	+	8.771
	=	93.90

Advagene Biopharma Co (ROCO:6709) Total Assets Explanation

Total Assets is connected with ROA %.

Advagene Biopharma Co's annualized ROA % for the quarter that ended in Jun. 2023 is

ROA %	=	Net Income (Q: Jun. 2023 )	/	( (Total Assets (Q: Dec. 2022 )	+	Total Assets (Q: Jun. 2023 ))	/ count )
	=	-93.258	/	( (140.838	+	93.904)	/ 2 )
	=	-93.258	/	117.371
	=	-79.46 %

Note: The Net Income data used here is two times the semi-annual (Jun. 2023) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Advagene Biopharma Co's Asset Turnover for the quarter that ended in Jun. 2023 is

	Asset Turnover
=	Revenue (Q: Jun. 2023 )	/	( (Total Assets (Q: Dec. 2022 )	+	Total Assets (Q: Jun. 2023 ))	/ count )
=	0	/	( (140.838	+	93.904)	/ 2 )
=	0	/	117.371
=	0.00

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Advagene Biopharma Co Total Assets Related Terms

Thank you for viewing the detailed overview of Advagene Biopharma Co's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Advagene Biopharma Co (ROCO:6709) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Advagene Biopharma Co Ltd (ROCO:6709) » Definitions » Total Assets

Comparable Companies

Traded in Other Exchanges

N/A

Address

Sector 1, Neihu Road, 6 Floor, No.308, Neihu District, Taipei, TWN, 114

Website

http://www.advagene.com.tw

Advagene Biopharma Co Ltd is a Taiwan based immune-modulatory platform-based drug developer. The company has completed technology transfer with DCB for detoxified LT Adjuvant Technology Platform. Its product development includes nasal spray influenza vaccine (LT-Flu), allergy vaccines (LT-Allergy), and other vaccines.

Advagene Biopharma Co (ROCO:6709) Headlines

No Headlines